Literature DB >> 15770516

Mechanisms of the development of androgen independence in prostate cancer.

Alan So1, Martin Gleave, Antonio Hurtado-Col, Colleen Nelson.   

Abstract

The effectiveness of androgen ablation in the management of advanced prostate cancer is of limited duration, with the median length of response being only 18-24 months. The transition of the prostate cancer cell to an androgen independent phenotype is a complex process that involves selection and outgrowth of pre-existing clones of androgen-independent cells (clonal selection) as well as adaptive up-regulation of genes that help the cancer cells survive and grow after androgen ablation (adaptation). These two mechanisms share an important pre-requisite characteristic: prostate cancers are heterogeneous tumours comprised of various subpopulations of cells that respond differently to androgen withdrawal therapy. This tumour heterogeneity may reflect either a multifocal origin, adaptation to environmental stimuli, and/or genetic instability of the initial cancer. This review will reexamine the different mechanisms that enable prostate cancer cells to proliferate in an androgen depleted environment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770516     DOI: 10.1007/s00345-004-0473-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  88 in total

Review 1.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  Her-2-neu expression and progression toward androgen independence in human prostate cancer.

Authors:  S Signoretti; R Montironi; J Manola; A Altimari; C Tam; G Bubley; S Balk; G Thomas; I Kaplan; L Hlatky; P Hahnfeldt; P Kantoff; M Loda
Journal:  J Natl Cancer Inst       Date:  2000-12-06       Impact factor: 13.506

Review 3.  The biology of hormone refractory prostate cancer. Why does it develop?

Authors:  J T Isaacs
Journal:  Urol Clin North Am       Date:  1999-05       Impact factor: 2.241

4.  Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas.

Authors:  A Wellmann; C Thieblemont; S Pittaluga; A Sakai; E S Jaffe; P Siebert; M Raffeld
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

5.  Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer.

Authors:  R S D Brown; J Edwards; A Dogan; H Payne; S J Harland; J M S Bartlett; J R W Masters
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

Review 6.  Clusterin: physiologic and pathophysiologic considerations.

Authors:  M E Rosenberg; J Silkensen
Journal:  Int J Biochem Cell Biol       Date:  1995-07       Impact factor: 5.085

7.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

Authors:  A Hobisch; I E Eder; T Putz; W Horninger; G Bartsch; H Klocker; Z Culig
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.

Authors:  Z Culig; A Hobisch; M V Cronauer; A C Cato; A Hittmair; C Radmayr; J Eberle; G Bartsch; H Klocker
Journal:  Mol Endocrinol       Date:  1993-12

10.  Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.

Authors:  Susan L Ettinger; Richard Sobel; Tanis G Whitmore; Majid Akbari; Dawn R Bradley; Martin E Gleave; Colleen C Nelson
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

View more
  43 in total

Review 1.  [Stress proteins in prostate cancer. Challenge and promise].

Authors:  B A Hadaschik; S W Melchior; R D Sowery; A I So; M E Gleave
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

2.  Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.

Authors:  Bilal Bin Hafeez; Aditya Ganju; Mohammed Sikander; Vivek K Kashyap; Zubair Bin Hafeez; Neeraj Chauhan; Shabnam Malik; Andrew E Massey; Manish K Tripathi; Fathi T Halaweish; Nadeem Zafar; Man M Singh; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

3.  A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression.

Authors:  Wei Qi; Hong Wu; Lin Yang; Douglas D Boyd; Zhengxin Wang
Journal:  EMBO J       Date:  2006-12-14       Impact factor: 11.598

4.  Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model.

Authors:  Peng Ru; Robert Steele; Pratibha V Nerurkar; Nancy Phillips; Ratna B Ray
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-12

5.  Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts.

Authors:  Massimo Ammirante; Shabnam Shalapour; Youngjin Kang; Christina A M Jamieson; Michael Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-29       Impact factor: 11.205

6.  The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy.

Authors:  Tyler Etheridge; Jinning Liou; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Am J Clin Exp Urol       Date:  2018-06-15

7.  Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.

Authors:  Xi Zheng; Xiao-Xing Cui; Zhi Gao; Yang Zhao; Yong Lin; Weichung Joe Shih; Mou-Tuan Huang; Yue Liu; Arnold Rabson; Bandaru Reddy; Chung S Yang; Allan H Conney
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

8.  Efficacy of c-Met inhibitor for advanced prostate cancer.

Authors:  William H Tu; Chunfang Zhu; Curtis Clark; James G Christensen; Zijie Sun
Journal:  BMC Cancer       Date:  2010-10-14       Impact factor: 4.430

9.  LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.

Authors:  Tammy L Romanuik; Gang Wang; Olena Morozova; Allen Delaney; Marco A Marra; Marianne D Sadar
Journal:  BMC Med Genomics       Date:  2010-09-24       Impact factor: 3.063

10.  Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.

Authors:  T Terakawa; H Miyake; J Furukawa; S L Ettinger; M E Gleave; M Fujisawa
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.